Fremanezumab
Ajovy (fremanezumab) is an antibody pharmaceutical. Fremanezumab was first approved as Ajovy on 2018-09-14. It has been approved in Europe to treat migraine disorders. The pharmaceutical is active against calcitonin; calcitonin gene-related peptide 1.
Trade Name | Ajovy |
---|---|
Common Name | Fremanezumab |
Indication | migraine disorders |
Drug Class | Monoclonal antibodies: humanized, neural indications |
